NASDAQ$MLYS
Mineralys Therapeutics Inc · Q3 2024 earnings
Q3 2024 earnings · · Investor relations
Briefing
MLYS Q3 2024 — $10.0M revenue, 1.13 EPS
The Company expects to continue to incur substantial losses in the foreseeable future as a result of the Company’s research and development activities. Mineralys Therapeutics Inc reported Q3 2024 results. Diluted EPS came in at $1.13. Headline numbers extracted from the Form 10-Q press release; narrative is light because this row was processed without an LLM call.
- Revenue: $10.0M.
- Diluted EPS: $1.13.
- Filed on Form 10-Q (accession 0001933414-24-000057).
Headline financials
Revenue & EPS history
Mineralys Therapeutics · Revenue · Quarterly
$0
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 14 quarterly earnings reports · overlaid with Q3 2024
-1.0%
Avg return
Earnings day
-5.9%
Avg return
5 days after
+5.5%
Avg return
30 days after
53%
8 / 15 earnings
Positive
+10.0%
Q4 2024
Best reaction
-9.2%
Q4 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2026 | -2.9% | -2.9% | -21.3% | |
| Q3 2025 | +5.9% | -8.2% | -19.0% | |
| Q2 2025 | +0.4% | +13.5% | +174.6% | |
| Q1 2025 | +2.6% | +4.8% | +6.1% | |
| Q4 2024 | +10.0% | +6.0% | +47.5% | |
| Q3 2024 | -4.7% | -18.2% | -7.8% | |
| Q1 2024 | -7.7% | -10.9% | -10.3% | |
| Q4 2023 | -4.1% | -4.1% | -15.7% | |
| Q3 2022 | +0.7% | -20.4% | -14.8% | |
| Q3 2023 | +0.7% | -20.4% | -14.8% | |
| Q2 2023 | +0.5% | -3.7% | -8.9% | |
| Q2 2022 | +0.5% | -3.7% | -8.9% | |
| Q1 2023 | -4.3% | -4.0% | -1.2% | |
| Q1 2022 | -4.3% | -4.0% | -1.2% | |
| Q4 2022 | -9.2% | -12.3% | -22.0% | |
| Q4 2021 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro